Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hansa Biopharma AB ( (SE:HNSA) ) has provided an announcement.
Hansa Biopharma AB announced a restructuring plan aimed at optimizing resource allocation and improving operational efficiency, which includes a 20% workforce reduction. This strategic move is expected to save 40-50 MSEK annually and enhance the company’s ability to deliver value to shareholders and patients, pending negotiations with trade unions.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare immunological conditions. The company utilizes a proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 172,057
Current Market Cap: SEK1.62B
For an in-depth examination of HNSA stock, go to TipRanks’ Stock Analysis page.